Gonadotropin Releasing Hormone Analogue Therapy Alters Signal Transduction Pathways Involving Mitogen-Activated Protein and Focal Adhesion Kinases in Leiomyoma
Restricted accessResearch articleFirst published online January, 2003
Gonadotropin Releasing Hormone Analogue Therapy Alters Signal Transduction Pathways Involving Mitogen-Activated Protein and Focal Adhesion Kinases in Leiomyoma
Objective:Because gonadotropin releasing hormone analogue (GnRHa) therapy often causes leiomyoma regression, in part through alteration of growth factor and receptor expression, we determined whether GnRHa therapy alters the expression of extracellular signal-regulated kinase (ERK) and focal adhesion kinase (FAK), which are linked to intracellular signaling pathways activated by ovarian steroids, growth factors, and adhesion molecules.
Methods:Leiomyoma and matched unaffected myometrium were collected from women who received GnRHa therapy (n = 5) and untreated women (n = 10). We determined the expression of ERK1, ERK2, FAK, phosphorylated ERK (pERK1/2), and pFAK using Western blotting and immunohistochemical analysis.
Results:Leiomyoma and myometrium expressed ERK1 (44 kD), ERK2 (42 kD), and FAK (125 kD) at variable levels with increased ERK2, pERK, and FAK expression in leiomyoma. We found that GnRHa therapy resulted in a noticeable decrease in ERK2 and FAK, with significant reduction in pERK1/2 and low or undetectable levels of pFAK in both leiomyoma and myometrium compared with the untreated group (P < .05). Immunohistochemically ERK1, ERK2, FAK, pERK1/2, and pFAK were localized in smooth muscle cells and connective tissue fibroblasts in gnRHa-treated and untreated leiomyoma and myometrium, with considerable reduction in their intensity as indicated by HScore in GnRHa-treated tissues.
Conclusion:The data provide further evidence that leiomyoma regression induced by GnRHa is mediated in part through a mechanism involving suppression of signal transduction pathways involving growth factors or ovarian steroid and adhesion molecules.
1. Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril1993;60:642-646.
2.
2. Friedman AJ. Treatent of uterine myomas with GnRH agonists. Semin Reprod Endocrinol1993;11:154-161.
3.
3. Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis. J Obstet Gynaecol Res2000;26:325-331.
4.
4. Chegini N. Implication of growth factor and cytokine networks in leiomyomas. In: Hill J, ed. Cytokines in human reproduction. New York: Wiley & Sons, 2000:133-162.
5.
5. Chegini N, Ropng H, Dou Q, Kipersztok S, Williams RS. Gonadotropin releasing hormone (GnRH) and GnRH receptor gene expression in human myometrial and leiomyomta and the direct action of GnRH analogs on myometrial smooth muscle cells interaction with ovarian steroids in vitro. J Clin Endocrinol Metab1996;81:3215-3221.
6.
6. Raga F, Casan EM, Kruessel JS, et al. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod1998;59:661-669.
7.
7. Dou Q, Zho Y, Tarnuzzer RW, et al. Suppression of TGF-βs and TGF-β receptrors mRNA and protein expression in leiomyomata in women receiving gonadotropin releasing hormone agonist therapy. J Clin Endocrinol Metab1996;81:3222-3230.
8.
8. Upadhyaya NB, Doody MC, Googe PB. Histological changes in leiomyomata treated with leuprolide acetate. Fertil Steril1990;54:811-814.
9.
9. Wu X, Blanck A, Olovsson M, Moller B, Lindblom B. Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRHa treatment. Acta Obstet Gynecol Scand2001;80:497-504.
10.
10. Gustavsson I, Englund K, Faxen M, Sjoblom P, Lindblom B, Blanck A. Tissue differences but limited sex steroid responsiveness of c-fos and c-jun in human fibroids and myometrium. Mol Hum Reprod2000;6:55-59.
11.
11. Rintala S, Kujansuu E, Teisala K, Rantala I, Kivinen S, Tuimala R. GnRh analogues and uterine leiomyomas. Effect of hormone replacement therapy on cell proliferation. Gynecol Obstet Invest1999;48:2276-2279.
12.
12. Englund K, Blanck A, Gustavsson I, et al. Sex steroid receptors in human myometrium and fibroids: Changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab1998;83:4092-4096.
13.
13. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab1998;83:1253-1255.
14.
14. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev2001;22:153-183.
15.
15. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem2001;276:36869-36872.
16.
16. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol1999;13:829-836.
17.
17. Cheng KW, Leung PC. The expression, regulation and signal trasduction pathways of the mammalian gonadotropin-releasing hormone receptor. Can J Physiol Pharmacol2000;78:1029-1052.
18.
18. Kraus S, Naor Z, Seger R. Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res2001;32:499-509.
19.
19. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERa expression in breast cancer cells. Mol Endocrinol2001;15:1344-1359.
20.
20. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer2001;95:247-254.
21.
21. Taylor CV, Letarte M, Lye SJ. The expression of integrins and cadherins in normal human uterus and uterine leiomyomas. Am J Obstet Gynecol1996;175:411-419.
22.
22. Mechtersheimer G, Barth T, Quentmeier A, Moller P. Differential expression of beta 1 integrins in nonnepolatic smooth and striated muscle cells and in tumors derived from these cells. Am J Pathol1994;144:1172-1182.
24. Panetti TS. Tyrosine phosphorylation of paxillin, FAK, and p130CAS: Effects on cell spreading and migration. Frontiers Biosci2002;7:d143-d150.
25.
25. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta2001;1540:1-21.
26.
26. Parson JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: A regulator of focal adhesion dynamics and cell movement. Oncogene2000;19:5606-5613.
27.
27. Jones RJ, Brunton VG, Frame MC. Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI3-kinase. Eur J Cancer2000;36;1595-1606.
28.
28. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Advancer Res1999;76:1-20.
29.
29. Kornberg LJ. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck1998;20:745-752.
30.
30. Marshall DD, Kornberg LJ. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope1998;108:1413-1417.
31.
31. Leone M, Cucuccio S, Venturini PL, Valenzano-Menada M, Messeni Leone M, DeCecco L. Immunohistochemical localization of epidermal growth factor receptor in leiomyomas from women treated with goserelin depot. Horm Metab Res1991;23:442-445.
32.
32. Hori M, Imagawa S, Shimazaki J, Itabashi M, Hori M. Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor a mutation in advanced stage human breast cancer. Pathol Res Pract2000;196:817-826.
33.
33. Volmat V, Camps M, Arkinstall S, Pouyssegur J, Lenormand P. The nucleus, a site for signal termination by sequestration and inactivation of p42/p44 MAP kinases. J Cell Sci2001;114:3433-3443.
34.
34. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res2001;61:6500-6510.
35.
35. Gioeli D, Zecevic M, Weber MJ. Immunostaining for activated extracellular signal-regulated kinases in cells and tissues. Methods Enzymol2001;332:343-353.
36.
36. Macphee Dj, Lye SJ. Focal adhesion signaling in the rat myometrium is abruptly terminated with the onset of labor. Endocrinology2000;141:274-283.
37.
37. Owens LV, Xu L, Marston WA, et al. Overexpression of the focal adhesion kinase (p125FAK) in the vascular smooth muscle cells of intimal hyperplasia. J Vasc Surg2001;34:344-349.
38.
38. Tang DD, Gunst SJ. Selected contribution: Roles of focal adhesion kinase and paxillin in the mechanosensitive regulation of myosin phosphorylation in smooth muscle. J Appl Physiol2001;91:1452-1459.
39.
39. Taylor JM, Mack CP, Nolan K, Regan CP, Owens GK, Parsons JT. Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells. Mol Cell Biol2001;21:1565-1572.
40.
40. Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: Correlation with preinvasive and invasive phenotypes. Clin Cancer Res2000;6:2417-2423.
